Rendering Protein-Based Particles Transiently Insoluble for Therapeutic Applications

Department of Chemistry, University of North Carolina, Chapel Hill, North Carolina 27599, USA.
Journal of the American Chemical Society (Impact Factor: 12.11). 05/2012; 134(21):8774-7. DOI: 10.1021/ja302363r
Source: PubMed


Herein, we report the fabrication of protein (bovine serum albumin, BSA) particles which were rendered transiently insoluble using a novel, reductively labile disulfide-based cross-linker. After being cross-linked, the protein particles retain their integrity in aqueous solution and dissolve preferentially under a reducing environment. Our data demonstrates that cleavage of the cross-linker leaves no chemical residue on the reactive amino group. Delivery of a self-replicating RNA was achieved via the transiently insoluble PRINT protein particles. These protein particles can provide new opportunities for drug and gene delivery.

Download full-text


Available from: Jin Wang
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We prepared paclitaxel-loaded disulfide-crosslinked human serum albumin nanoparticles ( PTX-HSA-NPs) in a microfluidic platform. The entire process includes four steps, i.e., a pretreatment step to partially reduce albumin, a mixing and co-precipitation step, a reaction step, and a dialysis step. Two important factors dominate the successful preparation of stable PTX-HSA-NPs: one is the choice of the anti-solvent in the co-precipitation step, and the other is the reaction time in the reaction step. We demonstrated that the drug-loaded nanoparticles are stable against dilution by the inter-albumin disulfide bonds, but still have a quick drug release profile in the intracellular-mimicking reduction environment. Through cell studies, we showed that the albumin nanoparticle carriers are safe and characterized the cell toxicity of the paclitaxel-loaded nanoparticles with cell lines of human breast cancer cells (MCF-7).
    Preview · Article · Feb 2013 · Chemical Communications
  • [Show abstract] [Hide abstract]
    ABSTRACT: This review surveys selected methods of manufacture and applications of microdevices-miniaturized functional devices capable of handling cell and tissue cultures or producing particles-and discusses their potential relevance to nanomedicine. Many characteristics of microdevices such as miniaturization, increased throughput, and the ability to mimic organ-specific microenvironments are promising for the rapid, low-cost evaluation of the efficacy and toxicity of nanomaterials. Their potential to accurately reproduce the physiological environments that occur in vivo could reduce dependence on animal models in pharmacological testing. Technologies in microfabrications and microfluidics are widely applicable for nanomaterial synthesis and for the development of diagnostic devices. Although the use of microdevices in nanomedicine is still in its infancy, these technologies show promise for enhancing fundamental and applied research in nanomedicine.
    No preview · Article · Mar 2013 · Molecular Pharmaceutics
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The complexity of tumor biology warrants tailored drug delivery for overcoming the major challenges faced by cancer therapies. The versatility of the PRINT(®) (Particle Replication In Non-wetting Templates) process has enabled the preparation of shape- and size-specific particles with a wide range of chemical compositions and therapeutic cargos. Different particle matrices and drugs may be combined in a plug-and-play approach, such that physico-chemical characteristics of delivery vectors may be optimized for biocompatibility, cargo stability and release, circulation half-life, and efficacy. Thus, the engineering of particles for cancer therapy with specific biophysical behaviors and cellular responses has been demonstrated via the PRINT process.
    Preview · Article · Apr 2013 · ACS Macro Letters
Show more